Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Jean‐Charles Soria et al.|The Lancet Oncology|2018Cited by 614
Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatelliteThomas G. P. Grünewald, Olivier Delattre, Didier Surdez et al.|Nature Genetics|2015Cited by 209